EVOFEM BIOSCIENCES®

INVESTOR PRESENTATION

OTCQB: EVFM

FORWARD-LOOKING STATEMENTS

This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases, you can identify forward looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "strategy," "objective," "designed," "suggest," "currently," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:

- The rate and degree of market acceptance of Phexxi® (lactic acid, citric acid and potassium bitartrate) vaginal gel and SOLOSEC® (secnidazole) 2 g oral granules
- Evofem's ability to successfully commercialize its products in the United States and to enter into successful partnerships to commercialize its products outside of the United States
- Evofem's estimates regarding expenses, revenues, financial performance and capital requirements, including the length of time its capital resources will sustain its operations, and its ability to raise additional capital to fund its operations when/if needed
- Evofem's ability to continue as a going concern
- Evofem's ability to comply with the provisions and requirements of its debt arrangements and to pay amounts owed pursuant to its debt arrangements
- Evofem's ability to retain members of its management and other key personnel and to expand its organization to accommodate potential growth
- Evofem's ability to maintain and protect its intellectual property position and its ability to obtain additional patent protection for its product for current and investigational indications
- The potential for changes to current regulatory mandates requiring payers to cover FDA-approved or -cleared contraceptives without cost sharing
- Evofem's ability to obtain or maintain third-party payer coverage and adequate reimbursement, and its reliance on the willingness of patients to pay out-of-pocket for its products absent full or partial third-party payer reimbursement
- Evofem's reliance on third-party providers and licensors, such as third-party manufacturers
- The presence or absence of any adverse events or side effects relating to the use of its products, and,
- Any other risk factors detailed in Evofem's filings from time to time with the U.S. Securities and Exchange Commission including, without limitation, the 10-K for the year ended December 31, 2023, filed with the SEC on March 27, 2024, 10-Q for the quarter ended September 30, 2024, filed on November 14, 2024, and any subsequent filings.

The forward looking statements in this presentation represent Evofem's views only as of the date of this presentation, December 11, 2024, and Evofem expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evofem's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this presentation are qualified in their entirety by this cautionary statement.

This presentation discusses estimates and other statistical data made by independent parties and by Evofem relating to market size and growth and other data about its industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

EVOFEM: WOMEN'S SEXUAL AND REPRODUCTIVE HEALTH INNOVATION

U.S. biopharma company commercializing innovative products to address unmet needs in women's sexual and reproductive health

phexxi® (lactic acid, citric acid, and potassium bitartrate) Vaginal Gel 1.8%, 1%, 0.4%

- Birth Control: hormone-free, on-demand prescription contraceptive vaginal gel
- $18.2M net sales in 2023

solosec® secnidazole 2g Oral Granules

- FDA-approved single-dose antimicrobial agent, taken orally
- Treatment for bacterial vaginosis (BV) and trichomoniasis

43.3M POTENTIAL PHEXXI USERS IN THE U.S.[1]

phexxi® (lactic acid, citric acid, and potassium bitartrate) Vaginal Gel 1.8%, 1%, 0.4%



10.3M women use non-prescription contraceptives

Non-Rx methods: barrier methods; withdrawal; periodic abstinence; tracking; other

13.0M women use no contraceptive at all

20.0M women use prescription contraceptives

Rx hormonal oral contraceptives, rings, patches, shots and IUDs/copper IUD

** Study predates commercial availability of Phexxi*

$8.3B

Contraceptive Market

(U.S. 2022)[2]

1. Daniels-K-and-Abma-J.-Current-Contraceptive-Status-Among-Women-Aged-15-49_NCHS-Data-Brief-Number-388-October-2020.pdf (evofem.com)
2. Grandview Research. U.S. Contraceptive Market Size, Share & Trends Analysis Report By Product (Pills, Intrauterine Devices (IUD), Condoms, Vaginal Ring, Subdermal Implants, Injectable), And Segment Forecasts, 2022 – 2030.

EVOFEM IS LEADING THE REVOLUTION

Innovative women's reproductive and sexual health solutions

THE FIRST AND ONLY ON-DEMAND, NON-HORMONAL PRESCRIPTION CONTRACEPTIVE VAGINAL GEL

- Vaginal pH Modulator
- Hormone-free
- FDA-approved for prevention of pregnancy
- Woman-controlled
- Used only when you need it
- Box of 12 Phexxi applicators

MOA - PHEXXI IS A pH MODULATOR

Optimal vaginal pH levels can range from 3.5 – 4.5



When semen (pH 7.1-8) enters the vagina, it raises the environmental pH level

Allows sperm to be mobile and swim up the reproductive canal

Phexxi keeps vaginal pH in the optimal range

Among subjects who used Phexxi in the registrational clinical trials, only 1.6% discontinued due to an adverse reaction.

This is lower than published rates of hormonal methods, which range from 9.6% to 20.1% discontinuation due to adverse reactions

EVERY 1% MARKET SHARE OF THE 43.3M WOMEN IN OUR ADDRESSABLE MARKET REPRESENTS SIGNIFICANT NET PRODUCT SALES

GROSS WAC per box of 12 Phexxi applicators	**$348.24**[1]	**Paid by the plan, not the woman** Under Federal law, most payers must cover FDA-approved contraceptives, including Phexxi, at no cost to women
	-	
Gross-to-Net Adjustments	**40%**	
	=	
Net to Evofem per box of Phexxi	**$208.94**	
	x	
Boxes each year per woman (avg.) (60 Phexxi applicators)	**5**	
	↓	
	$452 M	**PHEXXI ANNUAL NET SALES per each 1% market penetration**[2]

1. Effective January 1, 2024. WAC: Wholesale Acquisition Cost.
2. Annual net sales calculation: Net $ to EVFM per box * boxes/year/women * 433,000 women (1% of 43.3M women in Phexxi addressable market)

NET PRODUCT SALES GROWTH



PHEXXI SALES COVERAGE



DECEMBER 11, 2024

ACTIVATING PHEXXI UTILIZATION WITH SELECT PATIENT TYPES



- **Not using a prescription contraceptive**
- **Living with depression and anxiety**
- **Postpartum mother**
- **Struggles with her weight**
- **In need of non-systemic contraception**
- **Cancer survivor**
- **Wants non-hormonal**

WE ARE SUCCESSFULLY REACHING OUR TARGET PATIENT TYPES

CREATING THE VAGINAL PH MODULATOR CATEGORY

Changing the contraceptive counseling conversation to make it personal



THE GLP-1 OPPORTUNITY

GLP-1s include Ozempic, Wegovy, Mounjaro, and Zepbound

GLP-1s may make oral birth control pills less effective at certain points in dosing schedule

HCPs are to "advise females using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation." [1]

GLP-1 package inserts warn of potential risks to the fetus from exposure to these drugs during pregnancy [2]

JP Morgan analysts forecast that by 2030 in the U.S. alone[1]

- 30 million people in the U.S. – may be on GLP-1s [1]

Critical need for a non-systemic, non-hormonal method, like Phexxi

1. Zepbound Prescribing Information. https://uspl.lilly.com/zepbound/zepbound.html#pi
2. Based on Section 8.1, Use in Specific Populations: PREGNANCY in the PI for semaglutide and tirzepatide products
3. Schott C. *The increase in appetite for obesity drugs.* JP Morgan, November 29, 2023. https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs)

GLP-1 U.S. OPPORTUNITY: $224.56 MILLION TAM

2030 Forecast (U.S.)	**30 M** GLP-1 Users
	X
Women of Reproductive Age as % of U.S. Adult Population	25.59% [2]
	↓
Female GLP-1 Users of Reproductive Age	7.7 M
	X
% of Women of Reproductive Age using Oral Contraceptives (OCs)	14.0% [3]
	↓
Women on GLP-1s using OCs	1.1 M phexxi® targets

X $208.94 = $224.56 M

Net to Evofem per box of Phexxi

IN PHEXXI ANNUAL NET SALES

1. Schott C. *The increase in appetite for obesity drugs*. JP Morgan, November 29, 2023. https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs
2. Calculated based on 2022 population data from March of Dimes PeriStats https://www.marchofdimes.org/peristats/data?top=14&lev=1&stop=129&reg=99&obj=9&slev=1
3. Daniels-K-and-Abma-J.-Current-Contraceptive-Status-Among-Women-Aged-15-49_NCHS-Data-Brief-Number-388-October-2020.pdf (evofem.com)

SYNERGISTIC WOMEN'S HEALTH ACQUISITION

- Acquired in July 2024 from Lupin
- Synergistic women's health product
  - Aligns with strategic focus and leverages sales force
  - Both SOLOSEC and Phexxi address the vaginal biome
- $20M annual net sales run rate pre-Covid from BV indication only[1]
- Additional revenue potential in ex-U.S. markets (untapped partnering/licensing opportunity)
- Ten *Orange Book*-listed patents protect SOLOSEC in U.S. through Sept. 2035

1. SOLOSEC was not FDA approved for the treatment of trichomoniasis until July 2021

SOLOSEC: TWO FDA-APPROVED INDICATIONS

solosec
secnidazole
2g Oral Granules

BACTERIAL VAGINOSIS (BV) IN FEMALES 12 AND OLDER

- BV is the most common vaginal condition in women ages 15-44
- Raises pH of the vagina, which upsets the balance of the natural vaginal microbiome and can lead to symptoms of odor and discharge

BV affects 29% of U.S. population

TRICHOMONIASIS (TRICH) IN PEOPLE 12 AND OLDER

- Trich is the most common non-viral STI in the world[1]
- ~5.4M infections (U.S., 2018) - 2.1M women + 3.3M men

Trich affects 8.7% of U.S. population

SOLOSEC provides a complete course of treatment with one oral dose

1. Workowski KA, Bachmann LH, Chan PA, et al. CDC Sexually Transmitted Diseases Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(RR-04):1-192.

SOLOSEC DEMONSTRATED SOLID GROWTH UNTIL COVID-19 OUTBREAK

solosec
secnidazole
2g Oral Granules

$20M ANNUALIZED RUN RATE FOR TREATMENT OF BV ALONE[1]



1. SOLOSEC was not FDA approved for the treatment of trichomoniasis until July 2021

IN SUMMARY

We are executing our strategy to improve women's lives through innovative sexual and reproductive health products that address unmet and underserved medical needs

phexxi® (lactic acid, citric acid, and potassium bitartrate) Vaginal Gel 1.8%, 1%, 0.4%

The first and only FDA-approved hormone-free, on demand prescription contraceptive vaginal gel

- Approved and launched by Evofem in U.S. in 2020
- 2024 expected to be fourth consecutive year of annual net sales growth
- Regulatory filing in UAE expected Q4 2024 by our CGG commercial partner Pharma 1 to enable 2025 launch

solosec® secnidazole 2g Oral Granules

The first and only single-dose, oral product FDA-approved to treat both BV and Trich

- Relaunched in U.S. by Evofem in Q4 2024

Mitomic Endometriosis Test (MET™)

A blood-based diagnostic test for endometriosis

- Expected launch mid-2025